Mumbai: Sun Pharmaceutical Industries on Monday said that it has settled its dispute with US-based pharma firm MedImmune for marketing a generic version of latter’s Ethyol, a drug used in the treatment of head and neck cancer.
The company, along with its subsidiaries, has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the US district court of Maryland regarding generic version of Ethyol, drug maker Sun Pharma said in a filing to the Bombay Stock Exchange (BSE).
Under the settlement agreement, MedImmune would grant a licence to Sun Pharma for certain patents, permitting the India-headquartered company to continue marketing the generic version of Ethyol in the US, it further said.
“The settlement resolves the entirety of the litigation between the parties,” Sun Pharma said. The terms of settlement are confidential.
Ethyol is a prescription drug given through injection prior to each postoperative radiation treatment session for head and neck cancer. It is used to lower the rate of moderate to severe xerostomia (dry mouth).
Shares of Sun Pharma were trading at Rs1,164.20, down 0.66% in afternoon trade on the BSE.